Intralase — Merger or Acquisition (January 2007)
42 slides from Intralase's merger presentation, Jan 8, 2007
Slide 1: Advanced Medical Optics to Acquire IntraLase
Advanced Medical Optics to Acquire IntraLase January 8, 2007 Filed by IntraLase Corp. Pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: IntraLase Corp. Commission File No. 000-50939
Slide 2: Forward-Looking Statements
Forward-Looking Statements Our statements in this presentation on slides 4, 7, 9, 10, 19, 26-28, 30-34, 36, 37, and 39 and elsewhere that refer to AMO's financial projections or estimated future results, are forward looking statements that reflect the Company's current analysis of existing trends an
Slide 3: AMO's Refractive Leadership Strategy
AMO’S REFRACTIVE LEADERSHIP STRATEGY Jim Mazzo Chairman, President & CEO
Slide 4: AMO to Acquire IntraLase
AMO to Acquire IntraLase Transaction represents ideal strategic fit, advancing AMO’s growth plan to lead in ophthalmology’s premium segments • Uniquely positions AMO as the “Complete Refractive Solution” Further establishes AMO as the global refractive leader and definitive source for refractive inn
Slide 5: Advanced Medical Optics
x ° ADVANCED MEDICAL OPTICS
Slide 6: The Complete Refractive Solution
Femtosecond Lasers WaveFront Technologies Micro- keratomes CLC & Dry Eye Products OVDs & Phaco Aspheric IOLs Multifocal IOLs Phakic IOLs Excimer Lasers The Complete Refractive Solution Comprehensive combination of superior technologies and service unmatched in the industry
Slide 7: Global LVC Market
17% 2006: $643MM 2011: $893MM 5% 27% 5% Global LVC Market 2006-2011 CAGR of 7% driven by continuing conversion to customized, all laser LASIK procedure 1% 67% Source: Market Scope Comprehensive Report on Global Refractive Surgery Market, November, 2006 10% Excimer Lasers & Procedures Wavefront Diagn
Slide 8: U.S. Procedure Share by Segment
U.S. Procedure Share by Segment Procedure Per U.S. Laser Center U.S. Procedures by Segment The percent of procedures performed in corporate-owned laser centers is growing Institution-Owned Corporate-Owned Surgeon Owned Surgeon-Owned 57% Corporate-Owned 38% 5% Institution-Owned Source: Market Scope C
Slide 9: AXMO~
AXMO~ "THE NEW SHAPE OF VISIONS abd INTRALASE.*: CORP SMO™ ADVANCED MEDICAL OPTICS
Slide 10: Benefits of Custom All-Laser LASIK
Benefits of Custom All-Laser LASIK Defining a New Standard of LVC Care Provides leadership in advancing the practice of medicine with total systems approach; opportunity to grow market • Superior clinical outcomes • Enhanced safety profile • Less patient fear and improved satisfaction • Increased su
Slide 11: Wavefront-Guided LVC in the U.S.
Wavefront-Guided LVC in the U.S. Survey indicates that superior clinical outcomes continue to drive adoption of custom procedures 0% 10% 20% 30% 40% 50% Wavefront-guided is the best procedure for all patients Patients with higher levels of spherical error Patients with significant higher order aberr
Slide 12: Trends in CustomVue Mix of Procedures
Trends in CustomVue™ Mix of Procedures 0% 10% 20% 30% 40% 50% 60% 70% Q2 03 Q3 03 Q4 03 Q1 04 Q2 04 Q3 04 Q4 04 Q1 05 Q2 05 Q3 05 Q4 05 Q1 06 Q2 06 Q3 06 AMO TTM Custom Mix CustomVue™ treatment for low to moderate myopes Fourier wavefront upgrade, further improving CustomVue™ treatment precision Cus
Slide 13: Positive Impact on Retreatment Rates
Enhancement Rate Procedure Positive Impact on Retreatment Rates Surgeon experience shows how technological advancement translates into reduced enhancement rates <5% CustomVue® with Fourier Upgrade & Iris Registration ~10% CustomVue® with Fourier Upgrade 20-25% Conventional Ablation Courtesy: Mark Wh
Slide 14: International Expansion On Track
AMO Quarterly International Procedure Revenue Trend International Expansion On Track Success in replicating per-procedure model is evident in revenue growth and other key metrics $0 $1 $2 $3 $4 Q106 Q206 Q306 • 33% rise in international STAR S4IR ™ laser and WaveScan Wavefront ® diagnostic system pl
Slide 15: International Opportunity
International Opportunity European surgeons show growing preference for AMO and IntraLase technology -5% 5% 15% 25% 35% 45% 55% Others Zeiss/Meditec Wavelight B&L Alcon AMO -5% 5% 15% 25% 35% 45% 55% Others B&L Moria AMO IntraLase Use most often Would liket to use/acquire Source: Leaming Study 2005
Slide 16: U.S. LASIK Surgeon Outlook
U.S. LASIK Surgeon Outlook Expect rise in their WFG procedures using femtosecond keratomes and corresponding decline in conventional LASIK procedures 0% 5% 10% 15% 20% 25% 30% 35% Standard LASIK with conventional microkeratome Standard LASIK with femtosecond keratome WFG LASIK with conventional micr
Slide 17: Clinical Results Confirm Advantages
UCVA -- 1 Day PostOp UCVA -0.03 ± 0.11 Mechanical (n=346) -0.08 ± 0.10 Mean ± SD Femtosecond (n=240) 51% 82% 72% 89% 10% 27% 0% 25% 50% 75% 100% 20/12.5+ 20/16+ 20/20+ 20/40+ p=0.00 Clinical Results Confirm Advantages Study pairing AMO’s StarS4 TM CustomVue TM procedure with IntraLase TM showed fast
Slide 18: IntraLase Overview
INTRALASE OVERVIEW Bob Palmisano President & CEO 18
Slide 19: Key Benefits for IntraLase
Key Benefits for IntraLase • Transaction creates a refractive powerhouse - Two biggest names in refractive surgery come together to expand the market - Companies offer complementary products and services • IntraLase customers and patients worldwide will benefit from the industry’s most advanced LVC
Slide 20: About IntraLase
About IntraLase • Provides LASIK surgeons with outcomes superior to bladed microkeratome • 518 lasers installed at September 30, 2006 • Over 1,000,000 procedures sold worldwide • Business model driven by high-margin annuity streams • Proven success collecting international procedure fees • Rapid ado
Slide 21: How the IntraLase laser works
TO The ultra-fast laser uses an infrared light beam, generating up to 60,000 pulses TIME: 15-30 SECONDS per second, to prepare an optimal corneal architecture below the flap. Using an “inside-out” process, the IntraLase laser is precisely focused to a point within the cornea, where thousands of micr
Slide 22: IntraLase Procedure Trends
4,000 0 32,000 81,000 162,000 IntraLase Procedure Trends U.S. International 362,000 Thru 9/30/06 (in thousands) 30,000 84,000 192,000 243,000 30,000 80,000 160,000 162,000 200,000
Slide 23: IntraLase Method: U.S. Market Share Steadily Advancing
5% 10% 16% 25% IntraLase Share of Corneal Flaps 30% 10% 5% The IntraLase Method™: U.S. Market Share Steadily Advancing 0% 5% 10% 15% 20% 25% 30% Q4 02 Q4 03 Q4 04 Q4 05 Q4 06 IntraLase Share of Corneal Flaps IntraLase estimates [Estimate]
Slide 24: The IntraLase Method
The IntraLase Method ™ • Better medicine…..compelling patient outcomes Provides LASIK surgeons with ability to create thin, uniform flap - Fewer complications and side effects = happier patients Recent Defense Logistics Agency contract award for U.S. Military and civilian personnel • Better business
Slide 25: Coming Together
COMING TOGETHER Jim Mazzo Chairman, President & CEO 25
Slide 26: Why the Time is Right
Why the Time is Right Advances AMO’s core strategy for leadership in premium ophthalmic market segments • Combine Advanced CustomVue ™ and FS technology in total systems approach that benefits practitioners and patients • Maximize Intralase’s strong and growing foundation and first- mover advantage
Slide 27: Seizing the Opportunity
Seizing the Opportunity Plan for capitalizing on our differentiable position • Define custom all-laser LASIK as standard of care > Maximize existing infrastructure > Demonstrate compelling clinical benefits through Phase IV research > Deploy practice marketing tools that drive a coherent message > E
Slide 28: Integration Planning
Integration Planning Goal is to leverage combined strengths and make transaction seamless to customer • Jane Rady and Bernie Haffey to co-lead integration oversight • Building on fundamental principles used and lessons learned in VISX and Pfizer acquisitions • Ensure seamless transition for customer
Slide 29: Operations and Financial Overview
OPERATIONS AND FINANCIAL OVERVIEW Randy Meier Executive Vice President, Operations CFO President, Global Eye Care 29
Slide 30: Slide 30
Slide 31: AMO Strategic Objectives
AMO Strategic Objectives Designed to build on core strengths and deliver sustained, profitable growth Eye Care Laser Vision Correction Cataract/Implants • Provide superior, differentiated technologies that serve premium markets and deliver high margins • Focus pipeline on new innovations with market
Slide 32: Transaction Summary
Transaction Summary • Agreed to buy IntraLase for $808 million • $25 per share all-cash offer for all of IntraLase’s fully diluted shares • Transaction expected to close by early Q207 • Conditions to closing - IntraLase stockholder approval - Customary regulatory approvals - Other conditions of merg
Slide 33: Financing Summary
Financing Summary • At Signing: > Committed all-bank financing provided by UBS, Bank of America and Goldman Sachs > Combination revolver and term loan, fully pre-payable, no financing fees until transaction closing and funding • At Closing: > Expectation is that between signing and closing, AMO will
Slide 34: AMO Credit Profile
AMO Credit Profile • Current AMO Debt Pre-Closing Bank Revolver 18.8 Convertible Notes 851.1 2.5% due 2024 246.1 1.375% due 2025 105.0 3.25% due 2026 500.0 Total $869.9 Debt/Adjusted LTM EBITDA 2.9x • Pro Forma Debt and Leverage at Closing (est. 3/31/07) Bank Revolver 187.5 Bank Term Loan 350.0 High
Slide 35: Integration Synergies
Integration Synergies • Estimated annualized synergies of $25-$30 million > Approximately two-thirds derived from cost savings, primarily operating expenses • Expect to realize $10-$15 million by year-end 2007 • Expect to realize full benefit in 2008
Slide 36: AMO Sales Mix and Pro Forma Sales Mix
LVC 22% Eye Care 28% AMO Sales Mix YTD Q306 Pro Forma Sales Mix YTD Q306 LVC 31% Eye Care 24% LVC Sales Business unit’s sales would represent to represent more than 30% of AMO’s total consolidated sales on pro forma basis Cataract/Implant 45% Cataract/Implant 50%
Slide 37: 2007 and 2008 Guidance
2007 and 2008 Guidance $1.40-$1.55 $1,150-$1,175 $2.25-$2.40 Adjusted EPS $1,350-$1,370 Revenue (in millions) Guidance is provided on a non-GAAP basis. For information on use of non-GAAP financial measures, see “Investors” at www.amo - inc.com , in “Historical Financials” under “Investor Resources”
Slide 38: Acquisition-Related Charges
Acquisition-Related Charges • Total acquisition-related charges and integration costs related to the transaction estimated to be approximately $70 million - approximately 50% expected within 120 days of closing includes severance, insurance and advisor costs - the remainder expected to be taken in 2
Slide 39: Summary
SUMMARY Jim Mazzo Chairman, President & CEO
Slide 40: Key Takeaways
Key Takeaways Positions AMO as the “Complete Refractive Solution” Defines a New Standard of Care • Fortifies fundamental strategy to serve the full range of refractive vision needs • Comprehensive combination of superior technologies and service unmatched in industry • Provides leadership in advanci
Slide 41: Non-GAAP Adjusted EPS Guidance Note
Our guidance for adjusted EPS for and is provided on a non-GAAP basis. The company’s adjusted EPS guidance excludes the impact of charges or write-offs associated with acquisitions, reorganization or recapitalizations, and unrealized gains or losses on derivative instruments. The company believes th
Slide 42: Solicitation of Proxies
Solicitation of Proxies IntraLase intends to file with the SEC a proxy statement and other relevant materials in connection with the proposed transaction. The proxy statement will be mailed to the stockholders of IntraLase. Investors and security holders of IntraLase are urged to read the proxy stat